HEPC

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。流行病学和生物学证据支持慢性丙型肝炎感染和2型糖尿病之间的关联。然而，清除丙型肝炎病毒（HCV）是否与改善糖代谢有关尚不清楚。为了解决这个问题，我们提出了一项为期2年的前瞻性研究，研究对象是开始接受慢性肝炎治疗的个体。C感染。该项目的具体目的是：确定丙型肝炎治疗对葡萄糖耐量、胰岛素抵抗和胰岛素分泌的影响。参与者将在开始丙型肝炎治疗前一周进行研究访问，并在治疗期间每3个月进行一次研究访问。每次访问将包括标准化的访谈、人体测量和2小时的口服葡萄糖耐量胰岛素水平测试。在获得书面知情同意后，将从医疗记录中获取额外的临床数据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Epidemiologic and biologic evidence support an association between chronic hepatitis C infection and type 2 diabetes mellitus. However whether clearance of hepatitis C virus (HCV) is associated with improved glucose metabolism is not known. To address this issue, we propose a 2-year prospective study of individuals initiating therapy for chronic hepatitis. C infection. The specific aim of the project is: To determine the effects of hepatitis C treatment on glucose tolerance, insulin resistance, and insulin secretion. Participants will undergo research visits 1 week prior to initiating hepatitis C therapy and every 3 months during therapy. Each visit will consist of a standardized interview, 'anthropometry, and a 2-hour oral glucose tolerance test with insulin levels. Additional clinical data will be obtained, following written informed consent, from medical records.